Search

Displaying results 8091 - 8100 of 10000 in total
  1. Drug

    ST-36

    go.drugbank.com/drugs/DB17275
    Experimental

    ST-36 is a cell-penetrating dominant-negative form of activating transcription factor 5. In 2017, it received orphan drug designation by the FDA for the treatment of glioma.[L47341]

  2. Drug

    HMI-203

    go.drugbank.com/drugs/DB18520
    Investigational

    HMI-203 is an investigational gene therapy developed by Homology Medicines, Inc. … It consists of a recombinant adeno-associated virus (AAV) serotype HSC15 (rAAVHSC15) encoding human iduronate-2-sulfatase (hIDS).

  3. Drug

    BMS-791826

    go.drugbank.com/drugs/DB15023
    Investigational

    BMS-791826 is under investigation in clinical trial NCT03198013 (A Study of Pharmacokinetics (PK) and Pharmacodynamics (PD) in Relation to Prednisolone in Healthy Males).

  4. Drug

    Methylmalonic Acid

    go.drugbank.com/drugs/DB04183
    Experimental

    A malonic acid derivative which is a vital intermediate in the metabolism of fat and protein. Abnormalities in methylmalonic acid metabolism lead to methylmalonic aciduria. … This metabolic disease is attributed to a block in the enzymatic conversion of methylmalonyl CoA to succinyl CoA. [PubChem]

  5. Drug

    Brifentanil

    go.drugbank.com/drugs/DB09172
    ExperimentalIllicit

    Brifentanil (also known as A-3331) is an analog of fentanyl, a potent opioid. This drug is classified as an opioid analgesic and was developed in the early 1990s.

  6. Drug

    COVID-19 convalescent plasma

    go.drugbank.com/drugs/DB15692
    Investigational

    [L14333] This investigational COVID-19 treatment is currently available through three main pathways: use in registered clinical trials, use through the expanded access COVID-19 protocol (21 CFR 312.305 … clinical trial results for the safety or efficacy of COVID-19 convalescent plasma, early results from 5000 patients under the FDA expanded access program suggest that convalescent plasma transfusion in

  7. Drug

    N,N-dimethylarginine

    go.drugbank.com/drugs/DB01686
    Experimental

    Asymmetric dimethylarginine (ADMA) is a naturally occurring chemical found in blood plasma. … It is a metabolic by-product of continual protein modification processes in the cytoplasm of all human cells which is closely related to L-arginine, a conditionally-essential amino acid.

    Synonyms: guanidino-N,N-dimethylarginine, N(G),N(G)-Dimethylarginine
  8. Drug

    Ruserontinib

    go.drugbank.com/drugs/DB21555
    Investigational

    Ruserontinib is a small molecule drug. The usage of the INN stem '-tinib' in the name indicates that Ruserontinib is a tyrosine kinase inhibitor. … Ruserontinib is under investigation in clinical trial NCT04716114 (A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated).

  9. Drug

    Enbezotinib

    go.drugbank.com/drugs/DB21565
    Investigational

    Enbezotinib is a small molecule drug. The usage of the INN stem '-tinib' in the name indicates that Enbezotinib is a tyrosine kinase inhibitor. … Enbezotinib is under investigation in clinical trial NCT04161391 (Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations).

  10. Drug

    Utatrectinib

    go.drugbank.com/drugs/DB21295
    Investigational

    Utatrectinib is a small molecule drug. The usage of the INN stem '-trectinib' in the name indicates that Utatrectinib is a tropomyosin receptor kinase (TRK) inhibitor. … Utatrectinib is under investigation in clinical trial NCT01468324 (AZD7451 for Recurrent Gliomas). Utatrectinib has a monoisotopic molecular weight of 382.17 Da.